支气管流变成形术治疗慢性支气管炎:多中心临床试验12个月结果
该研究汇总两项研究共30例慢性支气管炎患者,接受双侧支气管流变成形术。6个月内无器械相关严重不良事件,4例操作相关严重不良事件,此后至12个月无严重不良事件。组织学显示杯状细胞增生评分显著降低,COPD评估测试和SGRQ评分在6个月和12个月均显著改善。
要点
- 支气管流变成形术在慢性支气管炎患者中可行,6个月内无器械相关严重不良事件。
- 组织学显示杯状细胞增生评分显著降低(P < 0.001)。
- 6个月时COPD评估测试和SGRQ评分较基线显著改善,12个月结果相似。
核心结论
- 该研究首次提供支气管流变成形术在有症状慢性支气管炎患者中可行性、安全性和初步结局的临床证据。
研究设计与样本
- 汇总分析两项研究,共纳入30例接受双侧支气管流变成形术的患者。
- 随访至6个月(主要结局)和12个月,评估不良事件、气道组织学和症状变化。
主要发现
- 30例患者中63%为男性,平均(SD)年龄67(7.4)岁,平均(SD)支气管舒张后FEV1为65%(21%)。
- 6个月内无器械相关严重不良事件,发生4例操作相关严重不良事件,此后至12个月无严重不良事件。
- 6个月内最常见非严重器械和/或操作相关事件为轻度咯血,发生率为47%(14/30)。
- 组织学显示平均杯状细胞增生评分显著降低(P < 0.001)。
- COPD评估测试评分从基线至6个月平均变化-7.9(中位数-8.0,P = 0.0002),SGRQ评分平均变化-14.6(中位数-7.2,P = 0.0002),12个月观察结果相似。
临床怎么用
- 对于有症状的慢性支气管炎患者,支气管流变成形术可能作为一种可行的干预选择,但需关注操作相关严重不良事件和咯血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Chronic bronchitis (CB) is characterized by productive cough with excessive mucus production, resulting in quality-of-life impairment and increased exacerbation risk. Bronchial rheoplasty uses an endobronchial catheter to apply nonthermal pulsed electrical fields to the airways. Preclinical studies have demonstrated epithelial ablation followed by regeneration of normalized epithelium.Objectives: To evaluate the feasibility, safety, and initial outcomes of bronchial rheoplasty in patients with CB.Methods: Pooled analysis of two separate studies enrolling 30 patients undergoing bilateral bronchial rheoplasty was conducted. Follow-up through 6 months (primary outcome) and 12 months included assessment of adverse events, airway histology, and changes in symptoms using the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test and St. George's Respiratory Questionnaire (SGRQ).Measurements and Main Results: Bronchial rheoplasty was performed in all 30 patients (63% male; mean [SD] age, 67 [7.4]; mean [SD] postbronchodilator FEV1, 65% [21%]; mean [SD] COPD Assessment Test score 25.6 [7.1]; mean [SD] SGRQ score, 59.6 [15.3]). There were no device-related and four procedure-related serious adverse events through 6 months, and there were none thereafter through 12 months. The most frequent nonserious, device- and/or procedure-related event through 6 months was mild hemoptysis in 47% (14 of 30) patients. Histologically, the mean goblet cell hyperplasia score was reduced by a statistically significant amount (P < 0.001). Significant changes from baseline to 6 months in COPD Assessment Test (mean, -7.9; median, -8.0; P = 0.0002) and SGRQ (mean, -14.6; median, -7.2; P = 0.0002) scores were observed, with similar observations through 12 months.Conclusions: This study provides the first clinical evidence of the feasibility, safety, and initial outcomes of bronchial rheoplasty in symptomatic patients with CB.Clinical trial registered with www.anzctr.org.au (ACTRN 12617000330347) and clinicaltrials.gov (NCT03107494).
引用
- Valipour A, Fernandez-Bussy S, Ing AJ, et al. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial. Am J Respir Crit Care Med. 2020. PMID: 32407638. doi:10.1164/rccm.201908-1546OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。